12:16 PM EDT, 10/03/2024 (MT Newswires) -- Bristol-Myers Squibb's ( BMY ) nivolumab (Opdivo) in combination with platinum-doublet chemotherapy was approved by the Food and Drug Administration as a neoadjuvant treatment for resectable non-small cell lung cancer in adults, the regulator said Thursday.

The decision was based on a randomized, double-blind, placebo-controlled study involving 461 patients with previously untreated and resectable NSCLC, the FDA said. Patients treated in the trial with nivolumab saw a significant improvement in event-free survival compared to chemotherapy alone, the regulator added.

Bristol-Myers Squibb's ( BMY ) shares were up 0.5% in recent trading.

Price: 54.01, Change: +0.25, Percent Change: +0.46